Document:

CONSULTING AGREEMENT

     This Consulting Agreement (the "Agreement") is made and entered into this
1st day of March 2006, by and between Gateway Distributors, Ltd., a Nevada
corporation ("GWDB"), whose principal place of business is 3220 Pepper Lane,
Las Vegas, Nevada 89120, and Steve Hayden  (the "Consultant") at 941 East Grand
Cerritos Ave, Las Vegas, Nevada 89120.

                                    RECITALS

     WHEREAS, Consultant is willing and capable of providing on a "best efforts"
basis various mergers and acquisition, feasibility, fairness opinions, legal
services and management services for and on behalf of GWDB in connection with
GWDB's mergers and acquisition projects, joint ventures, strategic alliances and
in connection with GWDB's compliance with state and Federal securities laws and
regulations; and

     WHEREAS, GWDB desires to retain the Consultant as an independent Consultant
to provide the above-described consulting services, and the Consultant desires
to be retained in that capacity upon the terms and conditions hereinafter set
forth.

     NOW THEREFORE, in consideration of the mutual promises and agreements
hereinafter set forth, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

CONSULTING SERVICES. GWDB hereby retains the Consultant as an independent
     Consultant to GWDB and the Consultant hereby accepts and agrees to such
     retention. The Consultant shall render to GWDB such services of an advisory
     or consultative nature in order to assist GWDB in the analysis of proposed
     divestiture/sales or acquisitions that may benefit GWDB; rendering of legal
     advice and services in the structuring of divestitures, acquisitions, joint
     ventures, strategic alliances, and other business related matters; and in
     order to permit GWDB to comply with all state and Federal securities laws
     and regulations.

TIME, PLACE AND MANNER OF PERFORMANCE. The Consultant shall be available for
     advice and counsel to the president and chief executive officer of GWDB,
     Rick Bailey, at such reasonable and convenient times and places as may be
     mutually agreed upon. Except as aforesaid, the time, place and manner of
     performance of the services hereunder, shall be determined in the sole
     discretion of the Consultant; however, the Consultant will provide a
     minimum of 250 hours.

TERM OF AGREEMENT. The term of this Agreement shall be for 12 months; commencing
     March 1, 2006 and terminating on March 1, 2007, unless terminated as set
     forth herein.

                                        1
<PAGE>
COMPENSATION. In consideration of the services to be provided for GWDB by the
     Consultant, GWDB hereby agrees to the following deliverable schedule for
     compensation:

     MERGERS AND ACQUISITIONS PROJECT CONSULTING. Upon execution of this
     --------------------------------------------
     Consulting Agreement and the commencement by the Consultant of services to
     be rendered pursuant to this Agreement, GWDB agrees to issue and deliver
     400,000,000 shares of common stock as compensation to the Consultant for
     the services to be rendered to GWDB. At the sole discretion of GWDB's board
     of directors or by GWDB's president and chief executive officer, GWDB may
     thereafter provide an additional number of shares of common stock at any
     time prior to the termination date of this Agreement, based upon progress
     reports, and/or within thirty (30) days of receipt, acceptance and approval
     by GWDB of the final deliverables. GWDB agrees, as soon as reasonably
     practicable, to register the Shares for resale under the Securities Act of
     1933, as amended, pursuant to a registration statement filed with the
     Securities and Exchange Commission on Form S-8 (or, if Form S-8 is not then
     available, such other form of registration statement then available).

CONFIDENTIALITY. The Consultant covenants that all information concerning GWDB,
     including proprietary information, which he obtains as a result of the
     services rendered pursuant to this Agreement shall be kept confidential and
     shall not be used by the Consultant except for the direct benefit of GWDB,
     nor shall the confidential information be disclosed by the Consultant to
     any third party without prior written consent of GWDB, provided, however,
                                                            -----------------
     that the Consultant shall not be obligated to treat as confidential, or
     return to GWDB copies of confidential information that (i) was publicly
     known at the time of disclosure to the Consultant; (ii) becomes publicly
     known or available thereafter other than by any means in violation of this
     Agreement or any other duty owed to GWDB by the Consultant, or; (iii) is
     lawfully disclosed to the Consultant by a third party or is required by any
     entity or court of competent jurisdiction or lawful request of any
     regulatory body or agency.

INDEPENDENT CONTRACTOR. The Consultant and GWDB hereby acknowledge that the
     Consultant is an independent contractor. The Consultant agrees not to hold
     himself out as, nor shall take any action from which others might
     reasonably infer that the Consultant is a partner or agent or a joint
     venturer with GWDB. In addition, the Consultant shall take no action that,
     to the knowledge of the Consultant binds, or purports to bind, GWDB to any
     contract or agreement.

EXPENSES. Consultant covers typical expenses expected to be incurred by the
     Consultant. For other extraordinary expenses beyond minor daily operating
     expenses to perform services under this Agreement, GWDB shall reimburse the
     Consultant on demand, net 30 days, for all expenses and other
     disbursements, provided these expenses and disbursements shall have GWDB's
     prior written approval and be verifiable with receipts and documentation as
     may be required under GAAP for accounting purposes

                                        2
<PAGE>
     of GWDB. All expense invoices pre-approved and received by GWDB will be
     addressed on a net 30-day basis.

TERMINATION. Notwithstanding any provision contained in this Agreement to the
     contrary, this Agreement may be terminated by GWDB at any time, for any
     reason, with or without cause, at the sole discretion of GWDB, with 30 days
     written notice to Consultant. Upon termination of this Agreement prior to
     the end of its anticipated expiration on July 31, 2003, with or without
     cause, GWDB has no requirement for payment of compensation or expenses of
     any kind, explicit or implicit, and GWDB assumes no liabilities either
     express or implied as a result of any terms of this Agreement. Until
     receipt of Consultant's deliverables by GWDB and the acceptance by GWDB of
     the adequacy and completeness of these deliverables in the sole discretion
     of GWDB, there is no creation of liabilities either express or implied
     under this Agreement; except that, at the sole discretion of GWDB, it may
     provide portions of compensation for work product received and accepted,
     and for project progress, as optional and voluntary interim compensation to
     Consultant by GWDB, up to the full amount to be paid. GWDB may also, at any
     time, terminate this Agreement for cause. For purposes of this Agreement
     the term "cause" means a termination of this Agreement during the term
     which is a result of (i) the Consultant's felony conviction or plea of "no
     contest" to a felony; (ii) the Consultant's willful disclosure of material
     trade secrets or other material confidential information related to
     Consultant's business; or (iii) the Consultant's willful and continued
     failure to substantially perform his duties for GWDB after a written demand
     for substantial performance is delivered by GWDB to the Consultant, which
     demand specifically identifies the manner in which GWDB believes that the
     Consultant has not substantially performed his duties, and which
     performance is not substantially corrected by the Consultant within 10 days
     of delivery of such demand. For purposes of the previous sentence, no act
     or failure to act on the Consultant's part shall be deemed "willful" unless
     done, or omitted to be done, by the Consultant not in good faith and
     without reasonable belief that the Consultant's action or omission was in
     the best interest of GWDB. In the accomplishment of the performance of such
     duties and responsibilities as are assigned to Consultant under the terms
     of this Agreement, Consultant shall at all times conduct himself in a
     professional manner and shall conform to those standards of ethical conduct
     as are generally expected from those performing such services in the
     business community

WORK PRODUCT. It is agreed that the Consultant retains all property rights with
     respect to the deliverables until payment in full for all work product is
     received by the Consultant from GWDB and GWDB has given final quality
     assurance approval to the work product and deliverables.

CONFLICT OF INTEREST. The Consultant shall be free to perform services for other
     persons. The Consultant will notify GWDB of his performance of consulting
     services for any other person, which could conflict with his obligations
     under this Agreement. Upon receiving such notice, GWDB may terminate this
     Agreement or may in writing waive

                                        3
<PAGE>
     the conflict concerns and continue with this Agreement at the sole
     discretion of GWDB.

INDEMNIFICATION FOR SECURITIES LAW VIOLATIONS. GWDB and the Consultant agree to
     mutually indemnify and hold each other and each officer, director and
     controlling person of GWDB or the Consultant harmless against any losses,
     claims, damages, liabilities and/or expenses (including any legal or other
     expenses reasonably incurred in investigating or defending any action or
     claim in respect thereof) to which the Consultant or GWDB or such officer,
     director or controlling person may become subject under the Securities Act
     of 1933, as amended, or the Securities Exchange Act of 1934, as amended,
     because of inappropriate actions of the Consultant or GWDB or their
     agent(s). GWDB and the Consultant will comply with all of the applicable
     laws of the Securities Act of 1933.

NOTICES. Any notices required or permitted to be given under this Agreement
     shall be sufficient if in writing and delivered or sent by registered or
     certified mail to the principal office of each party.

WAIVER OF BREACH. Any waiver by GWDB of a breach of any provision of this
     Agreement by the Consultant shall not operate or be construed as a waiver
     of any subsequent breach by the Consultant. Any waiver by Consultant of a
     breach of any provision of this Agreement by GWDB shall not operate or be
     construed as a waiver of any subsequent breach by GWDB.

ASSIGNMENT. This Agreement and the rights and obligations of the parties
     hereunder shall not be assignable, unless written authorization to assign
     the Agreement, rights and obligations hereunder is obtained from the other
     non-assigning Party.

Severability. All agreements and covenants contained herein are severable, and
------------
     in the event any of them shall be held to be invalid by any competent
     court, the Agreement shall be interpreted as if such invalid agreements or
     covenants were not contained herein.

ENTIRE AGREEMENT. This Agreement contains the entire agreement between the
     Parties, and may not be waived, amended, modified or supplemented except by
     agreement in writing signed by the Party against whom enforcement of any
     waiver, amendment, modification or supplement is sought. Waiver of or
     failure to exercise any rights provided by this Agreement in any respect
     shall not be deemed a waiver of any further or future rights.

WAIVER AND MODIFICATION. Any waiver, alteration or modification of any of the
     provisions of this Agreement shall be valid only if made in writing and
     signed by the parties hereto. Each party hereto, from time to time, may
     waive any of its rights hereunder without effecting a waiver with respect
     to any subsequent occurrences or transactions hereof.

                                        4
<PAGE>
COUNTERPARTS. This Agreement may be executed in counterparts, each of which
     shall be deemed an original but both of which taken together shall
     constitute but one and the same document.

GOVERNING LAW; VENUE. This Agreement shall be governed by and construed in
     accordance with the laws of the State of Nevada, and all issues of
     interpretation arising under this Agreement including, without limitation,
     issues with respect to capacity of the parties, execution and construction
     of the Agreement, the manner of performance under the Agreement, the
     validity of the Agreement and the rights and duties of the parties
     hereunder shall be decided in accordance with such law. The parties
     stipulate and agree that any and all legal actions or proceedings, which
     arise under this Agreement, shall be commenced within the State of Nevada,
     in a court of competent jurisdiction.

COSTS AND FEES. In the event that any of the parties hereto institutes any
     action, suit or proceeding to enforce the provisions of this Agreement, or
     for breach thereof, or to declare the rights of the parties with respect
     thereto, the prevailing party shall be entitled to recover, in addition to
     damages, injunctive or other relief, reasonable costs and expenses
     including, without limitation, costs and reasonable attorneys' fees
     incurred in the furtherance of such action, suit or proceeding.

NEGOTIATED TRANSACTION. The provisions of this Agreement were negotiated by both
     of the parties hereto, and said Agreement shall be deemed to have been
     drafted by both parties.

     IN WITNESS WHEREOF, the parties hereto have duly executed and delivered
this Agreement as of the day and year first above written.

CONSULTANT

-----------------------------------------
Steve Hayden

GATEWAY DISTRIBUTORS, LTD.

-----------------------------------------
Rick Bailey, Chairman/President

Date
     ------------------------------

                                        5IN THE MATTER OF GATEWAY DISTRIBUTORS, LTD., THE
RIGHT SOLUTION GATEWAY AND RICHARD BAILEY

                       ASSURANCE OF VOLUNTARY COMPLIANCE
                       ---------------------------------

     1.     This Assurance of Voluntary Compliance ("Assurance")(l) is entered
into by the Attorneys General of Arizona, California, District of Columbia,
Illinois, Kansas, Kentucky, Maryland, Michigan, Missouri, Montana, Nevada, North
Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Vermont, Washington and
Wisconsin (collectively referred to as the "Attorneys General") and Gateway
Distributors, Ltd., The Right Solution Gateway and Richard Bailey (collectively
referred to as "Respondents.")

     2.     Gateway Distributors, Ltd. is a Nevada corporation located at 3220
Pepper Lane, Las Vegas NV 89120. Gateway Distributors, Ltd. conducts business
using the name The Right Solution.

     3.     TRSG Corp. is a Nevada corporation that was located at 3035 E.
Patrick Lane, Suite 14, Las Vegas NV 89120. TRSG Corp. conducted business using
the name The Right Solution. Respondents no longer own TRSG Corp. and it is not
a party to this Assurance of Voluntary Compliance.

     4.     The Right Solution Gateway is a Nevada corporation located at 3220
Pepper Lane, Las Vegas NV 89120. The Right Solution Gateway conducts business
using the name The Right Solution.

     5.     Richard Bailey is the President and an owner of Gateway
Distributors, Ltd., and The Right Solution Gateway, and was the President and an
owner of TRSG Corp. The Attorneys

------------------------
   (1) This Assurance of Voluntary Compliance shall, for all necessary purposes,
also be considered an Assurance of Discontinuance.

                                        1
<PAGE>
General allege that Respondent Bailey, as an owner and officer of Gateway
Distributors, Ltd., TRSG Corp. and The Right Solution Gateway, possessed or
exercised the authority to control the policies and trade practices of Gateway
Distributors, Ltd., TRSG Corp. and The Right Solution Gateway; was responsible
for creating and implementing the unfair or deceptive policies and practices of
Gateway Distributors, Ltd., TRSG Corp. and The Right Solution Gateway that are
described herein; participated in the unfair or deceptive trade practices that
are described herein; directed or supervised those employees of Gateway
Distributors, Ltd., TRSG Corp. and The Right Solution Gateway who participated
in the unfair or deceptive trade practices that are described herein; and knew
or should have known of the unfair or deceptive trade practices that are
described herein and had the power to stop them, but rather then stopping them,
promoted their use.

                                  APPLICATION
                                  -----------

     6.     The terms of this Assurance apply to Respondents, and their
officers, agents, employees while serving as such, and their assigns and
successors in connection with any business in which they, either individually or
collectively, have an ownership interest or manage, that offers or sells
health-related products.

     7.     The terms of this Assurance set forth below shall apply to all of
the Respondents' advertising, offers for sale, or sales, either directly or
indirectly, to consumers of what are labeled, advertised, promoted or offered
for sale as health-related products (hereinafter "health- related products").
"Consumers" are purchasers or prospective purchasers of goods for personal,
family or household purposes.

                                        2
<PAGE>
                                  ALLEGATIONS
                                  -----------

     8.     The Attorneys General allege that Respondents labeled, advertised,
promoted, offered for sale, sold, and distributed topically applied
hormone-containing cream products that could not be lawfully offered or sold in
the United States.

     9.     The Attorneys General allege that Respondents' topically applied
hormone- containing cream products were unapproved new drugs that could not be
introduced into interstate commerce without prior approval from the United
States Food and Drug Administration ("FDA").

     10.     The Attorneys General allege that Respondents labeled, advertised,
promoted, offered for sale, sold, and distributed topically applied
hormone-containing cream products without first obtaining approval from the FDA.

     11.     The Attorneys General allege that Respondents, in the course of
labeling, advertising, promoting, selling and distributing their topically
applied hormone-containing cream products, misrepresented the legality of their
products to consumers.

     12.     The Attorneys General allege that Respondents, directly and through
their licensees, in the course of advertising, promoting, and marketing their
topically applied hormone- containing cream products, created and caused to be
mailed to consumers residing in each of the Attorneys Generals' states "Medical
Recall Notices" that stated, among other things:

          Medical Recall Notice
          ---------------------
          IMMEDIATE ACTION REQUIRED!
          Your Health Is At Risk!

          YOU MAY BE TAKING PRESCRIPTION DRUGS THAT HAVE
          BEEN DETERMINED TO BE HAZARDOUS TO YOUR HEALTH.

                                        3
<PAGE>
          INDICATIONS

          YOU ARE AT-RISK BY USING ANY FORM OFPRESCRIPTION
          -----------------------------------------------
          ESTROGEN OR PROGESTIN. IT HAS BEEN DETERMINED THAT
          ---------------------
          ALL FORMS OF THESE SYNTHETIC HORMONES ARE HAZARDOUS TO
          YOUR HEALTH, AND CAN LEAD TO: INCREASED RATES OF BREAST
          CANCER, CERVICAL CANCER, ENDOMETRIAL CANCER,
          GALLSTONES, GALL BLADDER DISEASE, PROLONGED VAGINAL
          BLEEDING, REDUCED CARBOHYDRATE TOLERANCE, REDUCED
          GLUCOSE TOLERANCE, THROMBOPHLEBITIS, VAGINAL
          CANDIDIASIS, JAUNDICE, HAIR LOSS, HYPERLIPEMIA,
          CYSTITIS-LIKE SYNDROMES, AMENORRHEA, ABDOMINAL CRAMPS,
          BLOATING, ELEVATED BLOOD PRESSURE, MENTAL DEPRESSION,
          NAUSEA AND VOMITING, SKIN RASHES, AND 20 TO 30 POUNDS
          OF EXCESS WEIGHT GAIN ON AVERAGE. UP TO 90% OF ESTROGEN
          IS DESTROYED IN LIVER. ESTROGEN REPLACEMENT THERAPY
          STOPS WORKING IN 5 TO 7 YEARS FOR MOST WOMEN...

          RECALLED TREATMENT... PRESCRIPTION ESTROGENS AND
          PROGESTINS...

          STOP KILLING YOURSELF! THE DETAILED INFORMATION IN THIS
          LETTER AND AUDIO CASSETTE IS TRUE, CLEAR AND
          CONVINCING. YOU HAVE HEARD MOST OF THESE DANGERS BEFORE
          - THAT PRESCRIPTION ESTROGENS AND PROGESTINS COME WITH
          HUGE AND SERIOUS SIDE EFFECTS THAT COULD COST YOU YOUR
          HEALTH, OR WORSE, THEY MAY COST YOU YOUR LIFE.

     13.     The Attorneys General allege that Respondents, directly and through
their licensees, in the course of advertising, promoting, and marketing their
topically applied hormone- containing cream products, mailed the aforementioned
Medical Recall Notices in envelopes that stated, in large type, that they
contained a "Drug Recall Warning."

     14.     The Attorneys General allege that Respondents, directly and through
their licensees, in the course of advertising, promoting, and marketing their
topically applied hormone-

                                        4
<PAGE>
containing cream products, falsely represented to consumers that prescription
estrogen and progesterone drug products are dangerous and have been recalled or
withdrawn from the market. In fact, no prescription progesterone or estrogen
drug products have been recalled or withdrawn from the market.

     15.     The Attorneys General allege that Respondents, directly and through
their licensees, in the course of advertising, promoting, and marketing their
topically applied hormone- containing cream products, misrepresented that their
advertisements were medical recall notices when, in fact, the advertisements
were nothing more than advertisements designed to advertise, market and promote
Respondents' topically applied hormone-containing products.

     16.     The Attorneys General allege that Respondents, directly and through
their licensees, in the course of advertising, promoting, and marketing their
topically applied hormone- containing cream products, mailed consumers who
resided in each of the Attorneys Generals' states an audiotape that contained an
interview of Betty Kamen, Ph.D conducted by Respondent Bailey.

     17.     The Attorneys General allege that Respondents, directly and through
their licensees, in the course of advertising, promoting, and marketing their
topically applied hormone- containing cream products, including in the Betty
Kamen, Ph.D. interview tape and Medical Recall Notices, made representations
that their topically applied hormone-containing cream products could be used to
cure, mitigate, treat or prevent diseases or affect the structure or function of
the body, including that the products may be used to treat or prevent PMS,
depression, osteoporosis and menopausal symptoms that occur naturally or as a
result of surgery.

     18.     The Attorneys General allege that Respondents' representations
concerning the

                                        5
<PAGE>
use and efficacy of their topically applied hormone-containing products were
unsubstantiated, false and/or misleading.

     19.     The Attorneys General allege that Respondents, directly and through
their licensees, in the course of advertising, promoting, and marketing their
topically applied hormone- containing cream products, represented that their
products were clinically proven when, in fact, no clinical testing had been
performed on Respondents' topically applied hormone-containing cream products.

     20.     The Attorneys General allege that Respondents' misrepresentations
that are described herein had the capacity, tendency and effect of misleading
consumers.

     21.     The Attorneys General allege that Respondents failed to inform
consumers of facts that were material, the omission of which deceived or tended
to deceive consumers, including Respondents' failure to inform consumers that
their topically applied hormone- containing products were drugs that could not
be lawfully marketed in the United States; that Respondents lacked
substantiation for the efficacy claims Respondents made regarding their
products; and that there has been no recall of estrogen and progesterone drug
products.

     22.     Respondents generally deny the allegations; assert that the FDA
issue is a correctable labeling issue; contend that they reasonably believed
that they had appropriate support for the representations made about the
efficacy of the product; contend that they ceased all involvement with the
Medical Recall Notice and its associated promotional campaign and ended their
relationship with its creators in July 1997, after a test period of several
months; and that only 120 bottles of the yam cream product were provided by the
Respondents to, and distributed by or through, the creator of the Medical Recall
Notice during this test period, which

                                        6
<PAGE>
bottles were sold by him for his own account.

     23.     By execution of this Assurance, the parties intend to resolve their
differences as provided for herein by providing for restitution to consumers and
the payment of a substantial civil penalty by Respondents and agreeing to
certain assurances regarding future conduct by Respondents and Richard Bailey.

                               TERMS OF ASSURANCE
                               ------------------

     24.     Respondents shall immediately cease and desist from engaging in any
unfair or deceptive trade practices in the offer or sale of health-related
products in violation of the consumer protection and trade practice statutes
listed herein at footnote 2 and/or the regulations promulgated pursuant to the
same.(2)

     25.     Respondents shall not make any express or implied statements in the
offer or sale of health-related products that have the capacity, tendency or
effect of deceiving or misleading consumers or that fail to state any material
fact, the omission of which deceives or tends to

----------------
    (2) Arizona Consumer Fraud Act, A.R.S. Section 44-1521, et seq.; California,
Bus. & Prof. Code Sec.Sec. 17200 et seq., and 17500 et seq.; District of
Columbia, Consumer Protection Procedures Act, D.C. Official Code Sec.Sec.
28-3901, et seq.; Illinois Consumer Fraud and Deceptive Business Practices Act,
815 ILCS 505/1, et seq.; Kansas Consumer Protection Act, K.S.A. 50-623, et seq.;
Kentucky KRS 367.110, et seq.; Maryland Consumer Protection Act, Md. Code Ann.,
Com. Law Sec. 13-101, et seq. (2002 Repl. Vol. and 2004 Supp.); Michigan
Consumer Protection Act, Mich. Comp. Laws Sec. 445.901, et seq.; Missouri
Consumer Protection Act, 407.020, et seq., RSMo 2000; Nevada Deceptive Trade
Practices Act, Nevada Revised Statutes, 598.0903 to 598.099, et seq.; North
Carolina Unfair and Deceptive Trade Practices Act, N.C. Gen. Stat. Sec. 75-1.1;
Ohio Consumer Sales Practice Act, R.C. 1345.01, et seq.; Oregon Revised Statutes
646.605 to 646.656; Pennsylvania Unfair Trade Practices and Consumer Protection
Law, Act of December 17, 1968, P.L. 1224, as amended, 73 P.S. Sec. 201-1, et
seq.; Consumer Protection Act of 1977, Tenn. Code Ann. Sec. 47-18-101, et seq.;
Deceptive Trade Practices - Consumer Protection Act, TEX. BUS. & COM. CODE ANN.
Sec. 17.41, et seq. (Vernon 2002 and Supp. 2005); Vermont Consumer Fraud Act, 9
V.S.A. Sec. 2451, et seq.; Washington, Consumer Protection Act, RCW 19.86, et
seq.; and Wisconsin Statutes Sec.Sec.100.18(1) and 100.207.

                                        7
<PAGE>
deceive consumers.

     26.     Respondents, in connection with the manufacturing, labeling,
advertising, promotion, offering for sale, sale, or distribution of
health-related products, shall not make any express or implied claim that the
products may be used in the diagnosis, cure, mitigation, treatment or prevention
of diseases in humans or animals unless the products are first approved by the
United States Food and Drug Administration as being safe and effective.

     27.     Respondents, in connection with the manufacturing, labeling,
advertising, promotion, offering for sale, sale, or distribution of
health-related products, shall not make any express or implied claim that the
products affect the structure or function of the body unless the products are
first approved by the FDA as being safe and effective.

     28.     Respondents shall not use the word "hormone" in any of the labeling
of their health-related products unless the products are first approved by the
FDA as being safe and effective.

     29.     Respondents, in connection with the manufacturing, labeling,
advertising, promotion, offering for sale, sale, or distribution of
health-related products, shall not make any representation, expressly or by
implication, concerning such products' efficacy, performance, safety or
benefits, unless, at the time the representation is made, Respondents possess
and rely upon competent and reliable scientific evidence that substantiates the
representation.

     30.     For purposes of this Assurance, "competent and reliable scientific
evidence" shall mean tests, analysis, research, studies, or other evidence based
on the expertise of professionals in the relevant area, that have been conducted
and evaluated in an objective manner by persons qualified to do so, using
procedures generally accepted in the profession to yield accurate and

                                        8
<PAGE>
reliable results. For health-related products, competent and reliable
scientific evidence shall include at least two adequate, and well-controlled,
double-blind clinical studies for purposes of this Assurance.

     31.     Respondents, in connection with the manufacturing, labeling,
advertising, promotion, offering for sale, sale, or distribution of
health-related products, shall not make any representations about research that
has been performed or other support for an advertising claim, including any
representations that their products have been clinically tested, unless
Respondents actually possess the research or support claimed in their
advertisements or solicitations, at the time the representations are made.

     32.     Respondents, in connection with the manufacturing, labeling,
advertising, promotion, offering for sale, sale, or distribution of
health-related products, shall not misrepresent the character or nature of any
advertisement for their product(s), including representing that an advertisement
is a medical recall notice, or that any product has been the subject of a
medical recall, unless the representations are, in fact, truthful.

     33.     Respondents shall print the statement "Advertisement Enclosed" in
at least 14- point bold faced type on any envelope sent to a consumer that
contains information used to advertise, market or promote any of Respondents'
health-related products.

     34.     Respondents shall not use the name "Health Notification Service" or
words of similar import to describe any company or business that they own or
operate.

     35.     Respondents, in connection with the manufacturing, labeling,
advertising, promotion, offering for sale, sale, or distribution of
health-related products, shall not make any representations about a particular
matter concerning a health-related product unless they clearly

                                        9
<PAGE>
and conspicuously state all facts, including any qualifying information
reasonably necessary to make the representation accurate and not misleading.

     36.     Respondents, in connection with the manufacturing, labeling,
advertising, promotion, offering for sale, sale, or distribution of
health-related products, shall make no statements or representations concerning
a health-related product that are ambiguous or make any of Respondents' other
statements or representations regarding the product ambiguous.

     37.     Respondents, in connection with the manufacturing, labeling,
advertising, promotion, offering for sale, sale, or distribution of
health-related products, shall not make any statements or representations
concerning a health-related product that contradict or conflict with any other
statements or representations Respondents make about the product at the same
time.

     38.     In the event that there is any change of federal or state law that
Respondents believe would impact their obligations under this Assurance,
Respondents may petition the appropriate Attorney(s) General, or in the case of
the State of Tennessee, a court of competent jurisdiction, to modify this
Assurance.

                                   RESTITUTION
                                   -----------

     39.     Respondents represent that they do not possess complete data
reflecting the identities of all of the consumers who purchased Respondents'
topically applied hormone- containing cream products. The provisions of this
paragraph are expressly premised upon the truthfulness and accuracy of the
representations made to the Attorneys General by the Respondents regarding the
completeness of the customer purchase and shipping data Respondents possess.
Within thirty (30) days of the Effective Date of this Assurance, Respondents
shall provide the Attorneys General with the information in their possession
that

                                       10
<PAGE>
identifies the consumers who purchased Respondents' products and whether the
purchases were of Respondents' topically applied hormone-containing cream
products. Respondents shall provide the information required under this
paragraph in the form of a list (hereinafter referred to as the "Consumer List")
that contains the following information:

          (i)     the name, address and phone number of every
          consumer who has purchased a product from the
          Respondents; and (ii) to the extent such information
          exists, the total

               amount, to date, of the payment(s) made by each
               consumer to Respondents for the purchase of any of
               Respondents' topically applied hormone-containing
               cream products.

Respondents shall provide the Consumer List to the Attorneys General in both
electronic and paper form. The electronic documents shall be in an ASCI,
tab-delimited format, or another format to which the Attorneys General agree.
The Consumer List shall be delivered to the Attorneys General by mailing the
information to: Office of the Maryland Attorney General, Consumer Protection
Division, 200 St. Paul Place, 16th Floor, Baltimore, MD 21202. The Attorneys
General may use the Consumer List to communicate with potential consumer
purchasers of Respondents' topically applied hormone-containing cream products
in furtherance of this Restitution Program and in order to otherwise carry out
and enforce the terms of this Assurance.

     40.     All consumers who purchased Respondents' topically applied
hormone-containing

                                       11
<PAGE>
cream products prior to the Effective Date(3) of this Assurance, and who file
restitution claims as outlined herein, are eligible to receive a refund of all
monies that they paid in connection with their purchase of the Respondents'
topically applied hormone-containing products, including but not limited to, the
purchase price of the product, sales tax, and shipping and handling (the
"Restitution Amount").

     41.     Respondents shall pay a Restitution Amount to all eligible
consumers who have either: (a) sent Respondents complaints, correspondence, or
other written, electronic or documented oral communications, in which the
consumer complained about Respondents' topically applied hormone-containing
cream products or requested a refund of his or her payments made to Respondents
to purchase the products; or (b) send Respondents, within 180 days of the
Effective Date of this Assurance (the "Claims Period"), any complaints,
correspondence, or other written, electronic or documented oral communications,
in which the consumer complains about Respondents' topically applied
hormone-containing cream products or requests a refund of his or her payments
made to Respondents to purchase the products (hereinafter referred to as "Claims
Letters").

     42.     Respondents shall also pay a Restitution Amount to all consumers
who either: (a) have sent any complaints, correspondence, or other written,
electronic or documented oral communications, to the Attorneys General, in which
the consumer either complained about Respondents' topically applied
hormone-containing cream products or requested a refund of his

---------------
     (3) The Effective Date of this Assurance of Voluntary Compliance shall be
the latest of the dates on which it is either executed by Respondents and each
of the Attorneys General or, in the case of Tennessee, the date on which it is
approved and entered by a Court of competent jurisdiction.

                                       12
<PAGE>
or her payments made to Respondents to purchase the products; or (b) send any
complaints, correspondence, or other written, electronic or documented oral
communications to the Attorneys General, in which the consumers complain about
Respondents' topically applied hormone-containing cream products or request a
refund of his or her payments made to Respondents to purchase the products
(hereinafter referred to as "Claims Complaints"). In order for a consumer to be
eligible to receive a refund under this paragraph, the consumer's Claims
Complaint must have been received by the Attorneys General during the Claims
Period.

     43.     Respondents shall pay the Restitution Amounts to consumers no later
than sixty (60) days after receiving the Claims Letters or Claims Complaints.
Respondents may reduce the Restitution Amounts they pay to consumers by an
amount equal to any refunds they paid eligible consumers in connection with
their purchase of Respondents' topically applied hormone- containing products.

     44.     Within Two Hundred and Seventy (270) days after the Effective Date
of this Assurance, Respondents shall provide the Attorneys General with copies
of all Claims Letters and Claims Complaints they received, as well as
documentation that the Restitution Amounts were paid to all of the consumers who
filed the Claims Letters and Claims Complaints or that full or partial payment
was withheld because of any refunds Respondents previously made to consumers.
The documentation required under this paragraph shall include both documentation
that a Restitution Amount has been paid, as well as a spreadsheet containing the
name and address of each consumer who was paid a Restitution Amount; the amount
of the Restitution Amount paid to each consumer; the date of the payment of the
Restitution Amount to each consumer; the amount of any refund previously paid to
the consumer; and the date of the

                                       13
<PAGE>
payment of any refund previously paid to the consumer. The spreadsheet
Respondents must provide the Attorneys General pursuant to this paragraph shall
be delivered by mailing the information to: Office of the Maryland Attorney
General, Consumer Protection Division, 200 St. Paul Place, 16th Floor,
Baltimore, MD 21202.

                                 CIVIL PENALTIES
                                 ---------------

     45.     Respondents shall pay the Attorneys General a civil penalty of One
Hundred Thousand Dollars ($100,000).

     46.     If Respondents pay all of the restitution due to consumers under
this Assurance, and the amount they pay to consumers exceeds $25,000, then the
civil penalty that Respondents shall pay the Attorneys General under this
paragraph shall be reduced by an amount equal to the aggregate amount of the
restitution paid to consumers that exceeded $25,000. If the Respondents pay all
of the restitution due to consumers under this Assurance, and the amount they
pay to consumers is less than $25,000, then the civil penalty that Respondents
shall pay the Attorneys General under this paragraph shall be increased by an
amount equal to the amount less than $25,000 of the restitution paid to
consumers under this Assurance.

     47.     Respondents shall pay the civil penalty due under paragraph 45 in
monthly installments of $5,000, or in the case of the final installment payment,
a portion thereof, on the first day of the first full month following the
Effective Date, until the entire civil penalty has been paid. Any payment
amounts due hereunder shall be made payable to the Attorney General of Maryland
and shall be delivered on or before the due date to Office of the Maryland
Attorney General, Consumer Protection Division, 200 St. Paul Place, 16th Floor,
Baltimore, MD 21202, or at such other places as the Attorneys General may from
time to time designate in writing, and

                                       14
<PAGE>
shall be made in lawful money of the United States in immediately available
funds.

     48.      The amount of the civil penalty and terms provided for its payment
that are provided for in paragraphs 45 through 47 herein are expressly premised
upon the truthfulness, accuracy, and completeness of the representations made by
Respondents to the Attorneys General, and information provided to the Attorneys
General, concerning Respondents' financial condition. If, in an action filed by
the Attorneys General, a Court were to find that Respondents misrepresented or
failed to disclose to the Attorneys General any material information concerning
their financial condition, the Court shall enter a judgment as a civil penalty
against Respondents, jointly and severally in favor of the Attorneys General. In
considering the greater penalty amount, the Court shall consider evidence
presented by the parties, including the intent of the Respondents, the actual
financial condition of the Respondents, the severity of the violations that are
alleged herein, and the purpose of the penalty, which is to punish Respondents
and deter future violations.

     49       From the Effective Date, for a period of two years, in order to
ensure that Respondents are complying with the terms of the Assurance, the
Attorneys General may request information from Respondents that may include
Respondents' banking records, accounting records or business records related to
the health-related products Respondents are offering and/or selling to
consumers. Respondents shall provide the requested information within sixty (60)
days of their receipt of any request for information made pursuant to this
paragraph as long as it is not unduly burdensome.

                                 CONFIDENTIALITY
                                 ---------------

     50.       If any of the Attorneys General receive a request for
confidential business records

                                       15
<PAGE>
provided by Respondents to the Attorneys General pursuant to this Assurance of
Voluntary Compliance, the Attorneys General shall comply with their applicable
disclosure laws and with any orders issued pursuant thereto.

                                    DEFAULT
                                    -------

     51.     If Respondents fail to make a monthly payment, make an assignment
for the benefit of their creditors, file or have filed against them any
proceedings under any reorganization, bankruptcy act or similar law, are
adjudicated bankrupt, or become insolvent, then all amounts due hereunder shall
become immediately due and payable without notice. Provided, however, that in
the event of a failure to make timely payments, Respondents shall be entitled to
a written notice from the Attorneys General of any such delinquent payment and
shall be given a period often (10) days to make the payment before their payment
obligations may be declared in default. If Respondents are provided an
opportunity to cure late payments on two occasions within any six month period,
they shall not be entitled to any further such opportunities to cure without the
express agreement of the Attorneys General. Any notice to Respondents under this
paragraph shall be made by mailing such notice, first class mail to Respondents
at 3220 Pepper Lane, Las Vegas NV, 89120 or to such other address as Respondents
may designate by notice to the Attorneys General.

     52.     Upon the occurrence of any default payment required under the terms
of this Assurance, Respondents hereby irrevocably authorize and empower any
attorney-at-law or Clerk of any court of competent jurisdiction in the State of
Maryland, or elsewhere, to appear at any time for the Respondents in any action
brought against the Respondents on this Assurance at the

                                       16
<PAGE>
suit of the Attorneys General, by and through the State of Maryland, Office of
the Attorney General, with or without declaration filed, as of any term, to
waive the issuing of service of process, and therein to confess or enter
judgment against Respondents, jointly and severally, for the entire unpaid sum
of amounts due hereunder, together with all costs and expenses of collecting
this Assurance, including reasonable attorney's fees. This authority to confess
judgment shall not be exhausted by any exercise thereof but shall continue from
time to time and at all times until payment in full or all the amounts due
hereunder has been made.

     53.     The Attorneys General of Arizona, California, District of Columbia,
Illinois, Kansas, Kentucky, Maryland, Michigan, Missouri, Montana, Nevada, North
Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Vermont, Washington and
Wisconsin, shall have jurisdiction in any proceeding instituted to enforce this
Assurance and any objections to venue are hereby waived.

     54.     The provisions of this Assurance shall be enforceable by the
Attorneys General in any court of competent jurisdiction located in Arizona,
California, District of Columbia, Illinois, Kansas, Kentucky, Maryland,
Michigan, Missouri, Montana, Nevada, North Carolina, Ohio, Oregon, Pennsylvania,
Tennessee, Texas, Vermont, Washington and Wisconsin.

     55.     No delay or failure by a party in exercising any right, power or
privilege under this Assurance shall affect such right, power or privilege; nor
shall any single or partial exercise thereof or any abandonment or
discontinuance of steps to enforce such right, power or privilege preclude any
further exercise thereof, or any other right, power or privilege.

     56.     Respondents hereby waive demand, diligence, presentment, protest
and notice of every kind. Any notice to Respondents that the Attorneys General
are required to make shall be

                                       17
<PAGE>
made by mailing such notice, first class mail to 3220 Pepper Lane, Las Vegas NV
89120 or to such other address as Respondents may designate by notice to the
Attorneys General, by and through the State of Maryland, Office of the Attorney
General.

                                    RELEASE
                                    -------

     57.     Following  full payment of the amounts due under this Assurance,
the Attorneys General shall release and discharge Respondents from all civil
causes of action that the Attorneys General could have brought under the
consumer protection statutes listed in footnote 2 related to the allegations set
forth herein for conduct prior to the date of this Assurance. Respondents agree
that if Respondents default on any monetary payment herein or file for
bankruptcy and thereby seek to either avoid or recover any payment made herein,
the Attorneys General may set aside this Assurance and pursue all legal remedies
to recover full restitution, costs, civil penalties and other remedies that
might have been available to the Attorneys General prior to entry of this
Assurance against Respondents. Nothing contained in this paragraph shall be
construed to limit the ability of the Attorneys General to enforce the
obligations that Respondents have under this Assurance or any other applicable
laws.

AGREED THIS         DAY OF                    , 2006.
           ---------       -------------------

FOR GATEWAY DISTRIBUTORS, LTD.

----------------------------------------
Richard Bailey, President
3220 Pepper Lane Las
Vegas NV 89120

      and

                                       18
<PAGE>
FOR THE RIGHT SOLUTION GATEWAY

----------------------------------------
Richard Bailey, President
3220 Pepper Lane Las
Vegas NV 89120

     and

----------------------------------------
Richard Bailey, Individually
3220 Pepper Lane Las Vegas
NV 89120

----------------------------------------
George A. Nilson
DLA Piper Rudnick Gray Cary
6225 Smith Avenue
Baltimore, MD 21209-3600
ATTORNEYS FOR RESPONDENTS

----------------------------------------
Steven B. Glade
7201 West Lake Mead, #108
Las Vegas, NV 89128
ATTORNEYS FOR RESPONDENTS

                                       19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]